Merck Serono SA
Division of Merck KGaA
www.merckserono.com
Latest From Merck Serono SA
Decade In Review: C-Suite Shifts At Family-Owned Indian Firms
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
The FDA Builds On Lessons Learned In Rebuilding Quality Metrics Program
US FDA officials tell industry that implementing a quality metrics program is an agency priority and that a rejiggered program will incorporate various elements of other quality metrics initiatives being piloted by the agency, industry and academia.
Welcome To Alexion 2.0
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.
On The Path To Regeneration: NovaGo’s New Approach To Stroke
Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ares-Serono SA
- Serono SA
- EMD Serono
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Germany
-
Germany
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Merck KGaA
- Senior Management
- Stefan Oschman, CEO, Prescription Medicines div.
- Contact Info
-
Merck Serono SA
Phone: (41) 6151 72 0
Frankfurter Str. 250
Darmstadt, 64293
Germany
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice